PHARMATEK · Gastroentérologie

Calculateur du score ABIC continu original

Calculer la valeur ABIC continue brute originale à partir de l’âge et de la bilirubine sérique, du RNI et de la créatinine sérique à l’admission, avec normalisation explicite des unités.

Révision clinique en cours

La révision clinique doit être complétée.

Cet outil fait partie de la bibliothèque PharmaTek. Son calcul reste indisponible au public jusqu’à la validation de sa formule, de ses limites et de ses sources.

Explorer les outils accessibles

Sources, population et validation

État: clinical-review-pending
Version de la méthode: Dominguez 2008 original continuous ABIC arithmetic v1: ABIC = [age (years) × 0.1] + [serum bilirubin (mg/dL) × 0.08] + [serum creatinine (mg/dL) × 0.3] + [INR × 0.8]; bilirubin accepts mg/dL or µmol/L and normalizes with 1 mg/dL = 17.1 µmol/L; creatinine accepts mg/dL or µmol/L and normalizes with 1 mg/dL = (10,000 / 113.1179) µmol/L; age and laboratory values represent the admission assessment, with laboratory values obtained at admission or within 48 hours; raw, continuous, unrounded output only
Population: Adults for whom applicability of the original Dominguez 2008 prospective, biopsy-proven alcohol-associated-hepatitis source context is independently established. The study cohort comprised 103 patients enrolled in Barcelona from 2000 through 2006, and the independent prospective confirmatory cohort comprised 80 biopsy-proven patients from Barcelona and Madrid. Age and serum bilirubin, INR, and serum creatinine must represent the same admission assessment; laboratory values must be obtained at admission or within 48 hours, with source values, analyte identities, units, timing, and compatible assay context independently verified.
Limites et exclusions: The source paper's published score groupings, any category or class assignment, individual outcome estimate, mortality or survival value, risk stratification, prognosis, reassurance, diagnosis or confirmation of alcohol-associated hepatitis, corticosteroid eligibility, treatment selection, monitoring, management, or any other clinical decision. · Use outside the original prospective, biopsy-proven Spanish source context without independently established applicability; automatic equivalence of clinically diagnosed or probable alcohol-associated hepatitis to biopsy-proven source enrollment; pediatric use; or extrapolation to another liver disease or nonhepatic population. · Measurements from different admission intervals; laboratory values obtained later than 48 hours; post-treatment, inferred, imputed, carried-forward, or default-normal values; missing components; or a partial score. · An unverified bilirubin fraction or creatinine analyte, unverified analyte, unit, assay, source-value, or timing identity, unsupported units, substitution of PT for INR, component rounding or clamping before substitution, an unverified floor or cap, or a modified ABIC equation.

Origine de l’outil PharmaTek

Outil importé de la bibliothèque PharmaTek de MDose. Aucune date de révision clinique indépendante n’est documentée dans cette version.

Bibliothèque source: PharmaTek · MDose
Version importée: 4b66536936ed
État de publication: Révision clinique en cours

POURSUIVRE AVEC MDOSE

Un outil. Un premier lien.

Recevez des nouvelles des outils ou discutez d’une collaboration. L’utilisation de PharmaTek reste accessible sans laisser vos coordonnées.

Médecins et partenaires